Gastroesophageal Cancer | Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer

Featuring perspectives from Prof Eric Van Cutsem, including the following topics:

Immune Checkpoint Inhibitors in Localized Gastroesophageal (GE) Cancers

• Introduction (0:00)
• Case: A man in his mid 50s with localized, poorly differentiated signet ring, mismatch repair-deficient advanced gastric adenocarcinoma — Sunnie Kim, MD (3:39)

HER2-Positive GE Cancers

• Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma and disease progression on FOLFOX/trastuzumab (PD-L1 CPS 0) — Dr Kim (19:22)

First-Line Treatment of Metastatic Gastric and GEJ Adenocarcinoma

• Case: A man in his early 40s who presents with metastatic GEJ adenocarcinoma (CLDN18.2-positive, PD-L1 CPS 2) in visceral crisis from lung metastases — Dr Kim (38:53)
• Case: A man in his mid 60s with metastatic GEJ adenocarcinoma (PD-L1 CPS 20) — Dr Kim (50:50)

CME information and select publications